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MaBACKGROUND Whether cyclosporine A (CsA) has beneﬁcial effects in reperfused myocardial infarction (MI) is debated.
OBJECTIVES This study investigated whether CsA improved ST-segment resolution in a randomized, multicenter phase
II study.
METHODS The authors randomly assigned 410 patients from 31 cardiac care units, age 63  12 years, with large
ST-segment elevation MI within 6 h of symptom onset, Thrombolysis In Myocardial Infarction (TIMI) ﬂow grade 0 to 1 in
the infarct-related artery, and committed to primary percutaneous coronary intervention, to 2.5 mg/kg intravenous
CsA (n ¼ 207) or control (n ¼ 203) groups. The primary endpoint was incidence of $70% ST-segment resolution 60 min
after TIMI ﬂow grade 3. Secondary endpoints included high-sensitivity cardiac troponin T (hs-cTnT) on day 4, left
ventricular (LV) remodeling, and clinical events at 6-month follow-up.
RESULTS Time from symptom onset to ﬁrst antegrade ﬂow was 180  67 min; a median of 5 electrocardiography leads
showed ST-segment deviation (quartile [Q]1 to Q3: 4 to 6); 49.8% of MIs were anterior. ST-segment resolution $70%
was found in 52.0% of CsA patients and 49.0% of controls (p ¼ 0.55). Median hs-cTnT on day 4 was 2,160 (Q1 to Q3:
1,087 to 3,274) ng/l in CsA and 2,068 (1,117 to 3,690) ng/l in controls (p ¼ 0.85). The 2 groups did not differ in LV
ejection fraction on day 4 and at 6 months. Infarct site did not inﬂuence CsA efﬁcacy. There were no acute allergic
reactions or nonsigniﬁcant excesses of 6-month mortality (5.7% CsA vs. 3.2% controls, p ¼ 0.17) or cardiogenic shock
(2.4% CsA vs. 1.5% controls, p ¼ 0.33).
CONCLUSIONS In the CYCLE (CYCLosporinE A in Reperfused Acute Myocardial Infarction) trial, a single intravenous
CsA bolus just before primary percutaneous coronary intervention had no effect on ST-segment resolution or hs-cTnT,
and did not improve clinical outcomes or LV remodeling up to 6 months. (CYCLosporinE A in Reperfused Acute
Myocardial Infarction [CYCLE]; NCT01650662; EudraCT number 2011-002876-18) (J Am Coll Cardiol 2016;67:365–74)
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ABBR EV I A T I ON S
AND ACRONYMS
CK = creatine kinase
CsA = cyclosporine A
ECG = electrocardiogram
hs-cTnT = high-sensitivity
cardiac troponin T
ITT = intention-to-treat
IV = intravenous
LV = left ventricle/ventricular
LV A/D = left ventricular
akinetic/dyskinetic
LVEF = left ventricular ejection
fraction
MI = myocardial infarction
mPTP = mitochondrial
permeability transition pore
PCI = percutaneous coronary
intervention
pPCI = primary percutaneous
coronary intervention
PROBE = PRospective Open,
Blinded Endpoint
Q = quartile
STEMI = ST-segment elevation
myocardial infarction
TIMI = Thrombolysis In
Myocardial Infarction
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366E arly, successful restoration of myocar-dial perfusion after a ST-segment ele-vation myocardial infarction (STEMI)
is the most effective way to reduce ﬁnal
infarct size and improve clinical outcome
(1–3). However, experimental and clinical
data have shown that reperfusion per se may
have harmful effects, the “myocardial reper-
fusion injury,” identiﬁed as a target for cardi-
oprotection (4–7). Mitochondria may play a
key role in reperfusion injury by opening a
nonspeciﬁc high-conductance channel called
the mitochondrial permeability transition
pore (mPTP), located in the inner mitochon-
drial membrane. Immediately after the onset
of myocardial reperfusion, irreversible open-
ing of the mPTP results in collapse of the
membrane potential, uncoupling of the respi-
ratory chain, and efﬂux of proapoptotic fac-
tors that may lead to cell death (8,9).
Experimental evidence suggests that
different interventions designed to prevent
mPTP opening may reduce myocardial infarct
size by an additional 30% to 50% in various
animal models (9). A single intravenous bolus
of cyclosporine A (CsA) before reperfusion
was reported to reduce creatine kinase (CK)
release by 40% in 58 STEMI patients treatedwith primary percutaneous coronary interventions
(pPCI) (10), and to attenuate the impairment of left
ventricular (LV) function over 6 months after myo-
cardial infarction (MI) in the same patients (11). This
proof-of-concept study created new enthusiasm in
targeting reperfusion for cardiac protection, with CsA
as prototypical agent (12,13), while also paving the
way to a larger multicenter study to verify these very
encouraging ﬁndings, before proceeding to a trial on
“hard” clinical endpoints. However, a double-blind
trial in 101 STEMI patients showed that CsA given
right before thrombolysis neither reduced MI size
nor improved clinical outcomes (14).SEE PAGE 375Experimental (15) and clinical (10) data on CsA
were deemed insufﬁcient to justify a real phase III
trial with hard clinical endpoints, such as the CIRCUS
(Cyclosporine and Prognosis in Acute Myocardial
Infarction [MI] Patients) trial, for which 1-year follow-
up results have been published (16). Therefore, we
planned and conducted a randomized, multicenter,
pragmatic, phase II trial enrolling a medium-sized
STEMI population undergoing pPCI with a 2-fold
purpose: ﬁrst, to verify, on a large scale, the efﬁcacy
of a single bolus of CsA in attenuating reperfusioninjury by detection of more complete resolution of
ST-segment elevation, and by reduction of infarct
size (measured as less release of biomarkers of
myocardial injury and improvement of echocardio-
graphically measured LV function); and secondly,
to assess the safety of a single intravenous (IV) bolus
of CsA given shortly before pPCI.
METHODS
The CYCLE (CYCLosporinE A in Reperfused Acute
Myocardial Infarction) trial (NCT01650662; EudraCT
number 2011-002876-18) was a multicenter, ran-
domized, open-label, controlled trial of CsA versus
no CsA (control) in patients with STEMI undergoing
pPCI with PRospective Open, Blinded Endpoint
(PROBE) design for the evaluation of the primary
endpoint. It was run according to the Declaration of
Helsinki of Good Clinical Practice. Regulatory
agencies and local ethics committees approved the
study protocol. All patients gave written informed
consent. CsA was purchased from a hospital phar-
macy (Azienda Ospedaliera Papa Giovanni XXIII,
Bergamo, Italy).
STUDY POPULATION. The study population comprised
patients >18 years of age with a ﬁrst STEMI (deﬁned as
nitrate-resistant chest pain $20 min and new
ST-segment elevation $0.1 mV in 2 contiguous leads).
In order to enroll patients with an area at risk large
enough to beneﬁt most from CsA, only patients with
ST-segment elevation in $3 leads in anterior MI and
ST-segment deviation in at least 4 leads in nonanterior
MI were randomized. Additional inclusion criteria
were presentation within 4 h of the onset of chest pain
(subsequently extended to 6 h); occlusion of the
culprit artery (Thrombolysis In Myocardial Infarction
[TIMI] ﬂow grade 0 to 1 at admission and before PCI);
and the clinical decision to treat with PCI. Exclusion
criteria were left bundle branch block in the presenting
electrocardiogram (ECG) (not permitting evaluation of
the resolution of ST-segment elevation); TIMI ﬂow
grade >1 in the culprit artery; coronary anatomy not
suitable for PCI; previous MI and/or previous coronary
artery bypass graft; thrombolytic therapy within 24 h
before randomization; current treatment (<10 days)
with CsA or contraindications to CsA; and severe renal
or hepatic insufﬁciency.
EXPERIMENTAL PROCEDURES. After signing the in-
formed consent form, eligible patients were randomly
assigned in a 1:1 ratio to CsA or nothing by an auto-
mated web-based system, using a permuted block
randomization scheme stratiﬁed by site of MI. The
bolus of 2.5 mg/kg of CsA (Sandimmune IV, Novartis,
Basel, Switzerland) was injected over 20 to 30 s into an
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367antecubital vein after coronary angiography, but just
before passage of the wire into the culprit artery (thus
avoiding any wire-related dissolution/fragmentation
of the occlusive thrombus), and at least 5 min before
PCI, to allow distribution of the drug. In the control
group, patients received only recommended treat-
ments according to STEMI European guidelines (3).
Coronary angiography was then done using standard
techniques to identify the culprit coronary artery and
to check that reperfusion had not occurred before PCI
(TIMI ﬂow grade 0 to 1 at randomization).
Two readers blinded to treatment allocation
analyzed the digitized angiograms for all stenoses,
thrombus burden, collaterals before reperfusion, and
TIMI ﬂow grade and rate, as well as myocardial blush
grade after reperfusion.
Essentials of the study design are shown in Online
Figure 1. Patient follow-up involved 4-week and
6-month (ﬁnal) visits (at which serious adverse events
were checked, with a cardiovascular examination and
measurement of vital signs [heart rate and blood
pressure]). A 12-lead ECG tracing was recorded at
hospital admission and 60 min after the ﬁrst evidence
of antegrade ﬂow following pPCI to assess the primary
endpoint of the study, resolution of ST-segment
elevation (see the following text).
Blood samples for central measurement of plasma
high-sensitivity cardiac troponin T (hs-cTnT) (ECLIA
Cobas 411, Roche Diagnostics, Rotkreuz, Switzerland)
were collected before coronary angiography, the next
morning, day 4, and 6 months after the study medi-
cation and stored in a central biobank at the Mario
Negri Institute in Milan, Italy. Cardiac troponins and
CK were assayed locally, recorded, and normalized by
the upper limit of normal of each clinical chemistry
laboratory for calculations.
A conventional 2-dimensional echocardiography
examination was done in each patient on day 4 and at
the 6-month visit, to assess global and segmental
LV function. Measurements were taken in at least 3
consecutive cycles for patients in sinus rhythm and
5 for patients with atrial ﬁbrillation, from the para-
sternal long-axis, mitral- and papillary-level short-
axis, and apical 2- and 4-chamber views. LV volumes
were calculated and normalized by body surface area,
and the modiﬁed biplane Simpson’s rule was applied
to calculate left ventricular ejection fraction (LVEF).
LV regional wall motion was evaluated using a
16-segment model (17). An index of the extent of LV
damage was obtained by dividing the number of
akinetic/dyskinetic segments by the total number of
segments evaluated (up to 16) and expressed as a
percentage. All echocardiographic data were stored
digitally in Digital Imaging and Communications inMedicine (DICOM) format for subsequent ofﬂine
analysis. Quality was monitored by centrally reading
10% of randomly sampled echocardiographic exami-
nations from each site.
The primary efﬁcacy endpoint was the incidence
of $70% resolution of ST-segment elevation 1 h
after pPCI, as previously described (18,19). This was
due to the assumption that in addition to being a
validated tool to assess the efﬁcacy of reperfusion
therapy, ST-segment resolution would provide an
indication of the outcome of PCI. ST-segment ele-
vations in all 12 leads were measured 20 ms after
the end of the QRS complex with an ad hoc–made
electronic caliper on digitized ECG tracings by a
reader blind to patient identiﬁcation and treatment.
ST-segment resolution was calculated as the differ-
ence between 60 min and baseline in the lead with
maximal ST-segment elevation at baseline (18).
Duplicate readings were taken on 10% of randomly
chosen ECGs, with a third reader in case of
disagreement.
The key secondary endpoint was the concentration
of hs-cTnT measured on day 4 after pPCI. This easy,
inexpensive, single-point measurement is closely
related to infarct size (20), LV function (21), and
clinical outcomes (22,23).
Other secondary endpoints (deﬁnitions provided
in the Online Appendix) were regional and global
LV function assessed on day 4 and 6 months, as well
as rehospitalization for cardiovascular reasons, all-
cause and cardiovascular death, heart failure, and
cardiogenic shock at 6 months.
STATISTICAL METHODS AND POWER CALCULATIONS.
Because the main analysis was done according to
the intention-to-treat (ITT) approach, all patients
randomized in the study were included. Baseline
characteristics by randomized treatment are pre-
sented as proportions for categorical variables and
compared by the chi-square test; continuous vari-
ables are reported as mean  SD or median (quartile
[Q]1 to Q3) and compared by a Student t test or the
Wilcoxon rank sum test, as appropriate. The primary
endpoint (complete ST-segment resolution [i.e.,
$70%, 60 min after PCI]) was analyzed with a
logistic regression model. Adjustment was made by
multivariable logistic regression for baseline charac-
teristics (number of ECG leads with ST-segment
deviation, ventricular tachycardia, and Rentrop
score $2) unbalanced between the 2 groups.
On the basis of previous data (18) a 55% incidence
of the primary endpoint was assumed in the placebo
arm. We calculated that 444 patients (222 patients per
group) were required for the study to have 80%
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368power to detect a 25% difference in the rates of
ST-segment resolution with a 5% dropout rate at a
2-sided alpha of 5%. The size of the trial also allowed
us to investigate the effects of treatment on circu-
lating levels of hs-cTnT on day 4 after pPCI. Assuming
a concentration of hs-cTnT of 2,700 ng/l on day 4
(SD: 2.1) in the control group, it would be possible to
detect a 25% difference with 90% power, and a
2-sided alpha of 5%. The study was not powered to
detect a treatment effect on the clinical events
deﬁned as secondary endpoints. Cumulative event
rates for the secondary endpoints (i.e., events
occurring over the 6-month follow-up) were esti-
mated using the Kaplan-Meier method. Hazard ratios,
95% conﬁdence intervals, and p values for compari-
son of the 2 groups were determined with the Cox
proportional hazards regression model. Treatment
effects on echocardiographic parameters related to
ventricular remodeling and on loge-transformed
concentrations of centrally assayed hs-cTnT were
examined by analysis of variance. All analysis of
variance models included the interaction between
study treatment and site of MI and the percentage of
left ventricular akinetic/dyskinetic (LV A/D) seg-
ments. Between-group comparisons of area under
the curves for the hs-cTnT concentrations measuredFIGURE 1 Patients’ Disposition for Analysis of the Primary Endpoin
410 patients presenting within 6
MI were ran
207 assigned to CsA
ITT analysis
(202 ECG available*‡)
4 protocol violations
26 post-PCI TIMI <3
203 PP analysis
(199 ECG available‡)
177 PP & optimally reperfused
(174 ECG available‡)
The population for the per-protocol analysis is deﬁned in the Methods s
the concomitant presence of 2 exclusion criteria: PCI not done and stud
measurable for ST-segment resolution and 1 for early death; controls: 9
resolution and 2 for early death. ‡ECG available ¼ baseline and 60-min
CYCLE ¼ CYCLosporinE A in Reperfused Acute Myocardial Infarction; EC
infarction; PCI ¼ percutaneous coronary intervention; PP ¼ per-protocoat admission, day 1, and day 4 were made with the
Wilcoxon rank sum test.
In an attempt to minimize the risk of a false-
negative result, we not only excluded patients who
did not undergo PCI or who received the wrong dose
of CsA (protocol violations) from the ITT population,
thus deﬁning the per-protocol population, but also
those with incomplete revascularization of the culprit
artery (i.e., TIMI ﬂow grade <3 at the end of the
procedure, thus deﬁning an “optimally reperfused”
group) (Figure 1). A 2-sided alpha level of 0.05 was
considered to indicate statistical signiﬁcance. All data
analyses were conducted with SAS software (SAS
Institute, Cary, North Carolina), version 9.2 or higher.
RESULTS
A total of 410 STEMI patients were enrolled from
January 19, 2012, to April 30, 2014, in 31 Italian cen-
ters: 207 received an IV bolus of CsA, and 203, who
served as controls, received conventional treatment.
In all, 80% were male, 40% were active smokers,
and 14% had diabetes. More than one-half of the
population was hypertensive. Pre-infarction angina
within 48 h before the index event was reported
in approximately one-half of the patients (Table 1).t, ST-Segment Resolution, in the CYCLE Study
 h from onset of symptoms of
domized
203 assigned to Control
ITT analysis
(192 ECG available*‡)
1 protocol violation
18 post-PCI TIMI <3
202 PP analysis
(192 ECG available‡)
184 PP & optimally reperfused
(175 ECG available‡)
ection. Two patients in the CsA group were excluded because of
y treatment wrong. *CsA arm: 4 patients were excluded for ECG not
patients were excluded for ECG not measurable for ST-segment
ECG available and ST-segment measurable. CsA ¼ cyclosporine A;
G ¼ electrocardiogram; ITT ¼ intention-to-treat; MI ¼ myocardial
l; TIMI ¼ Thrombolysis In Myocardial Infarction.
TABLE 1 Baseline Characteristics of the Study Population
Total
(N ¼ 410)
CsA
(n ¼ 207)
Control
(n ¼ 203) p Value
Age, yrs 62.9  12 62.5  12.4 63.2  11.6 0.59
Male 327 (79.8) 167 (80.7) 160 (78.8) 0.64
BMI, kg/m2 26.7  3.9 27.1  3.8 26.4  3.9 0.06
Current smokers 165 (40.2) 84 (40.6) 81 (39.9) 0.83
Diabetes mellitus 58 (14.2) 27 (13.0) 31 (15.3)
Type 1 4 (6.8) 2 (7.4) 2 (6.5) 0.52
Type 2 54 (93.2) 25 (92.6) 29 (93.5)
Hypertension 227 (55.4) 114 (55.1) 113 (55.7) 0.90
Dyslipidemia 155 (37.8) 72 (34.8) 83 (40.9) 0.20
Pre-infarct angina 185 (45.1) 91 (44.0) 94 (46.3) 0.63
Heart rate, beats/min 75  16 77  16 74  16 0.09
SBP, mm Hg 132  26 132  26 132  26 0.98
DBP, mm Hg 78  14 79  14 78  14 0.76
Killip class II–IV at entry 19 (4.6) 10 (4.8) 9 (4.4) 0.85
No. of ECG leads with
$1-mm deviation
5 (4–6) 5 (5–7) 5 (4–6) 0.01
In-hospital therapies
Aspirin 407 (99.3) 205 (99.0) 202 (99.5) 1.00*
Heparin 346 (84.4) 175 (84.5) 171 (84.2) 0.93
Thienopyridine 406 (99.0) 203 (98.1) 203 (100.0) 0.12*
Glycoprotein IIb/IIIa antagonist 182 (44.4) 90 (43.5) 92 (45.3) 0.71
Beta-blockers 331 (80.7) 164 (79.2) 167 (82.3) 0.44
Bivalirudin 99 (24.2) 46 (22.2) 53 (26.1) 0.36
ACEi/sartans 293 (71.5) 147 (71.0) 146 (71.9) 0.84
Statins 365 (89.0) 183 (88.4) 182 (89.7) 0.69
Symptoms to ﬁrst antegrade
ﬂow time, min
180  67 178  69 183  65 0.52
Anterior infarct 203 (49.5) 102 (49.3) 101 (49.7) 0.92
TIMI ﬂow before PCI
0 342 (83.4) 179 (86.5) 163 (80.3) 0.09
1 68 (16.6) 28 (13.5) 40 (19.7)
Stent implantation, 1–4 393/406 (95.9) 198/204 (97.0) 195/202 (97.0) 0.70
Values are mean  SD, n (%), median (interquartile range), or n/N (%). *Fisher exact test.
ACEi ¼ angiotensin-converting enzyme inhibitor; BMI ¼ body mass index; CsA ¼ cyclosporine A; DBP ¼
diastolic blood pressure; ECG ¼ electrocardiogram; PCI ¼ percutaneous coronary intervention; SBP ¼ systolic
blood pressure; TIMI ¼ Thrombolysis In Myocardial Infarction.
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369The 2 groups had a similar hemodynamic status,
depicted by blood pressure, heart rate, and Killip
class. They were also comparable for all major events
occurring before randomization (i.e., deﬁbrillation,
cardiopulmonary resuscitation, shock, bradycardia,
second- or third-degree atrioventricular block),
except ventricular tachycardia, which was reported
in 7 (3.5%) patients in the control group, but none in
the CsA group (p ¼ 0.007). Overall, nearly one-half of
the patients had an anterior MI. Median pain-to-ﬁrst
antegrade ﬂow time was 180  67 min, with a negli-
gible difference between the groups, showing that
there was no delay in starting pPCI attributable to the
CsA injection. The number of ECG leads with 1 mm
or more ST-segment deviation was signiﬁcantly
(p ¼ 0.01) higher in the CsA than in the control group.
Among the angiographic characteristics, distribution
of the culprit artery was comparable, with the left
anterior descending coronary artery the site of oc-
clusion in about one-half of the patients. The culprit
artery was totally occluded (TIMI ﬂow grade 0) in a
large proportion of patients in both groups (p ¼ 0.09).
Technical details of the procedures, such as number
and type of stents (drug-eluting vs. bare-metal stents)
and maximum pressure of the balloon inﬂation, did
not differ between the 2 groups (Online Table 1). PCI
was not done in 4 patients (3 in the CsA group and 1 in
the control group) for the following reasons: aortic
dissection; unsuitable anatomy; no occlusion; and
thrombus aspiration. CsA was not either given or the
wrong dose was given to 3 patients. In all, 49 patients
were excluded from the ITT population for the
analysis limited to patients fulﬁlling protocol re-
quirements and optimally reperfused: PCI not done in
4; wrong study treatment in 3 (2 patients with 2
criteria for exclusion); and incomplete reperfusion
(TIMI ﬂow grade <3) in 44 (Figure 1). There were
6 patients with Rentrop grade 2, corresponding to the
presence of collateral ﬂow, all in the control group
(Online Table 1).
PRIMARY ENDPOINT. Centrally read ST-segment reso-
lution of 70% or more at a median time of 61 min after
pPCI (61 min in the CsA group and 62 min in the
control group, p ¼ 0.73) occurred at similar rates in
CsA patients (105 of 202, 52.0%) and controls (94 of
192, 49.0%) (unadjusted p ¼ 0.55). After adjustment
for variables unbalanced for the randomized treat-
ment, such as the number of leads with ST-segment
deviation, Rentrop grade 2, and ventricular tachy-
cardia, the difference was still not signiﬁcant
(p ¼ 0.76). Analyzed as a continuous variable, median
(Q1 to Q3) ST-segment resolution was 71% (50% to
90%) in CsA and 69% (47% to 88%) in controls(p ¼ 0.55). The primary endpoint could not be calcu-
lated in 16 patients: 8 because of idioventricular
rhythm; 1 because of the presence of a pacemaker;
3 died before the second ECG could be recorded; and
4 for other reasons. Of the 16 patients with a missing
primary endpoint, 5 were in the CsA group and 11
were in the control group (p ¼ 0.12) (Figure 1). The
lack of effect of CsA on ST-segment resolution was
conﬁrmed when data were analyzed by MI site
(Central Illustration, panel A).
SECONDARY ENDPOINTS. The time course of cen-
trally assayed hs-cTnT did not differ in the CsA and
control groups (Figure 2). This was true on day 4, even
after stratiﬁcation by MI site (Central Illustration,
panel B). Median (Q1 to Q3) areas under the hs-cTnT
concentration versus time (entry to day 4) were,
CENTRAL ILLUSTRATION Cyclosporine in Reperfused STEMI: Effects on Primary and Secondary Endpoints in the CYCLE Trial
Ottani, F. et al. J Am Coll Cardiol. 2016; 67(4):365–74.
Effects of cyclosporine A on primary and selected secondary endpoints in the CYCLE trial in all patients (shaded area) and by infarct site. (A) Incidence
of $70% ST-segment resolution; (B) plasma concentrations of hs-cTnT on day 4; (C) LVEF on day 4; (D) percentage of LV A/D segments on day 4.
ANOVA ¼ analysis of variance; CsA ¼ cyclosporine A; CYCLE ¼ CYCLosporinE A in Reperfused Acute Myocardial Infarction; hs-cTnT ¼ high-sensitivity
cardiac troponin T; LV A/D ¼ left ventricular akinetic/dyskinetic; LVEF ¼ left ventricular ejection fraction; MI ¼ myocardial infarction; STEMI ¼ ST-segment
elevation myocardial infarction.
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370respectively, 268 (151 to 446) and 250 (141 to 444)
ng,ml1,h in CsA and controls (p ¼ 0.66). The
results of the centrally assayed hs-cTnT were
consistent with those of cardiac troponins and CK in
terms of peak levels (Online Figure 2) and time
courses (Online Figure 3), assayed locally, and
normalized by the upper limit of normal for each
laboratory. Analysis of the echocardiographic assess-
ment of LV remodeling was in full agreement with
these biomarkers with respect to CsA effects. The
LVEF was lower, as expected in anterior MIs, but
there was no difference between the CsA and controlgroups (p for treatment ¼ 0.16). The percentage of
LV A/D segments was higher in anterior MIs, and
decreased signiﬁcantly from day 4 to month 6,
although there was no difference between the 2 study
groups (p ¼ 0.61) (Central Illustration, panels C and D,
Online Table 2).
Consistent with the ﬁndings on ST-segment reso-
lution, myocardial blush grades 2 to 3 at the ﬁnal
angiography (a marker of successful reperfusion) did
not show any difference by study treatment: 77.3%
in CsA and 80.8% in controls (p ¼ 0.82) (Online
Table 1).
FIGURE 2 Time Course of hs-cTnT in the CsA and Control Groups
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TABLE 2 6-Month Secondary Endpoints by Intention-to-Treat
Patients With Events
at 6 Months (Adjudicated by
the Event Validation Committee)
Total
(N ¼ 410)
CsA
(n ¼ 207)
Control
(n ¼ 203)
HR (95% CI)
CsA vs. Control
p
Value
Death 18 (4.3) 12 (5.7) 6 (3.2) 1.98 (0.74–5.27) 0.17
CV death 13 (3.3) 9 (4.4) 4 (2.2) 2.24 (0.69–7.26) 0.18
Heart failure 44 (10.1) 21 (9.7) 23 (10.4) 0.91 (0.50–1.64) 0.75
Cardiogenic shock 9 (2.2) 6 (2.4) 3 (1.5) 1.99 (0.50–7.95) 0.33
All-cause mortality or HF or
cardiogenic shock
57 (13.5) 29 (13.9) 28 (13.4) 1.03 (0.61–1.73) 0.91
Rehospitalization for CV reasons 58 (14.3) 28 (14.3) 30 (14.6) 0.95 (0.57–1.59) 0.84
Values are n (%), unless otherwise noted. Percentages are product-limit survival estimates derived by the
Kaplan-Meier method.
CI ¼ conﬁdence interval; CsA ¼ cyclosporine A; CV ¼ cardiovascular; HF ¼ heart failure; HR ¼ hazard ratio.
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371Clinical events over the 6-month follow up are re-
ported in Table 2. Of the 18 patients who died,
12 (5.7%) in the CsA group and 6 (3.2%) controls
(p ¼ 0.17), a cardiovascular cause was adjudicated
in 13, of whom 9 (4.4%) were in the CsA group and
4 (2.2%) were controls (p ¼ 0.18). Six patients
(2.4%) in the CsA group and 3 (1.5%) in the control
group had cardiogenic shock (p ¼ 0.33), whereas
hospitalization for cardiovascular reasons and epi-
sodes of heart failure were equally distributed
across the 2 groups. The incidence of the combined
endpoint of all-cause mortality, heart failure, or
cardiogenic shock was similar: 29 (13.9%) in the
CsA group and 28 (13.4%) in the control group,
respectively (p ¼ 0.91).
PER-PROTOCOL ANALYSIS AND OPTIMALLY REPERFUSED
PATIENTS. In the per-protocol analysis, 102 (51.3%)
patients in the CsA group and 94 (49.0%) in the
control group (p ¼ 0.89, adjusted) had a ST-segment
resolution of at least 70%. Of the 349 patients who
were optimally reperfused, fulﬁlling study protocol
and with ST-segment resolution measured, 94 (54.0%)
CsA and 88 (50.3%) control patients (p ¼ 0.69,
adjusted) showed a ST-segment resolution $70%. The
analysis showed a 6-month all-cause mortality of 3.4%
versus 2.2% (p ¼ 0.49) and cardiovascular mortality of
2.8% versus 1.1% (p ¼ 0.25). As with ITT, the combined
endpoint of all-cause mortality, heart failure, or
cardiogenic shock was not different in the 2 groups:
21 (11.9%) in the CsA group and 23 (12.5%) in the control
group (p ¼ 0.88). Echocardiography indicated larger
LV volumes both on day 4 and at 6 months with CsA,
reaching statistical signiﬁcance in the per-protocol
analysis (Online Table 3).
SAFETY. Great care was taken to monitor patients in
the ﬁrst few hours after the index event for rare acute
reactions to intravenous CsA, which have been re-
ported and attributed to 1 of the excipients, ricinoleic
acid (24–26). In fact, no anaphylactoid reactions were
reported during the CYCLE trial. Only 1 serious
adverse drug reaction was reported in the whole trial,
a patient in the CsA group who died after surgery
for myocardial rupture 23 days after the index MI
(Table 3).
DISCUSSION
The present multicenter, controlled clinical trial does
not conﬁrm the previous ﬁndings of a marked cardiac
protective effect of CsA in the setting of timely reper-
fused acute MI by means of pPCI (10). All selected trial
endpoints, such as ST-segment resolution, circulating
levels of troponins, and LV remodeling, with clinical
outcomes, consistently showed that an IV bolus of CsAjust before recanalization of an occluded coronary
artery did not enhance the beneﬁcial effect of reper-
fusion. The slight (but not statistically signiﬁcant)
excess in all-cause and cardiovascular mortality with
CsA, but not in nonfatal clinical events, and the ten-
dency towards larger LV volumesmight even suggest a
harmful effect. Our ﬁndings provide strong support
and expand previous neutral or negative pre-clinical
(15,27) and clinical (14,16) studies with CsA.
The representativeness of the large number of
cardiology centers involved in the trial protects
TABLE 3 Adverse Drug Reactions Reported in CYCLE
Total
(N ¼ 410)
CsA
(n ¼ 207)
Control
(n ¼ 203)
p
Value
Patients with adverse reactions
to the study drug
4 (1.0) 4 (1.9) 0 (0.0) 0.12
Allergic reaction 2 (0.5) 2 (1.0) 0 (0.0)
Acute renal failure — — —
Hypertensive crisis — — —
Other 2 (0.5) 2 (1.0) 0 (0.0)
SADR 1 (0.2) 1 (0.5) 0 (0.0)
Values are n (%).
CsA ¼ cyclosporine A; SADR ¼ serious adverse drug reactions.
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372against bias that could originate from the lack
of blinding of the investigators. Moreover, readers
unaware of patients’ characteristics or allocation
to study treatment centrally analyzed ECGs and
troponin by (PROBE design).
Because reperfusion injury starts in the very early
phase of recanalization of an infarct-related artery,
patients in a network of coronary care units of the
Italian National Health Service were enrolled as soon
as possible in this pragmatic trial, so that average
time from symptom onset to ﬁrst anterograde ﬂow
was only 3 h, compared with 4.5 h in the CIRCUS
trial (16). This very short interval between self-
reported onset of symptoms and reperfusion of the
culprit artery was similar in both study groups,
ensuring that the CsA injection time did not delay
successful recanalization of the culprit artery.
To increase the chance of showing a beneﬁcial ef-
fect of CsA, “small” infarcts, deﬁned by the number of
leads with ST-segment elevation on the presenting
ECG tracing, were excluded. Slightly bigger, ECG-
deﬁned infarcts in the CsA group than in the control
group could have instead maximized the beneﬁcial
effect. Additionally, the infarct-related artery had to
be a large, occluded coronary artery (i.e., TIMI ﬂow
grade 0 to 1 before randomization), and the CsA bolus
had to be given before reopening the culprit vessel
(not even the passage of the guidewire was allowed
before drug injection) in order to have the CsA
distributed in the bloodstream at the time of
recanalization.
A major determinant of myocardial salvage and
of the long-term outcome after MI is the extent
of reperfusion. In the CYCLE trial, the similarity
between study groups in the rate of ST-segment
resolution, TIMI ﬂow grade 2 or 3, and myocardial
blush post-pPCI strengthens the conclusions of CsA’s
lack of efﬁcacy. Even when effects were analyzed by
MI site (i.e., anterior or nonanterior), circulating hs-
cTnT, ST-segment resolution, and echocardiographyconsistently showed no changes attributable to CsA.
The results of the anterior MI subgroup are consistent
with those of the CIRCUS trial, while expanding
the ﬁndings to patients with other infarct locations.
Also consistent with these results, intravenous CsA
conferred no advantages in terms of ST-segment
resolution in the per-protocol analysis and in a
further analysis that excluded 5 patients with
protocol violations and 44 patients nonoptimally
reperfused.
In order to avoid possible confounding with
different pharmaceutical preparations, the CYCLE
study (unlike the CIRCUS trial) used Sandimmune
(Novartis), as in the earlier pilot study that showed
beneﬁt from CsA (10). In the CIRCUS trial, a formu-
lation without ricinoleic acid was used, with the aim
of reducing the risk of acute anaphylactoid reactions.
As in previous studies on cardioprotection, we paid
special attention to circulating levels of cardiac tro-
ponins measured by a contemporary high-sensitivity
assay, rather than to CKs, assayed either locally or
centrally: the results failed to show any potential
beneﬁcial effect of CsA (Central Illustration, panel B,
Figure 2, Online Figures 2 and 3).
The present study is not the ﬁrst to show the fail-
ure of agents targeted to reperfusion injury for
cardioprotection (28). In other cases, some acute
protective action was apparent, which did not appear
to lead to substantial long-term beneﬁts (29,30).
Cardioprotective effects leading to long-term beneﬁt
on cardiac function have been shown only for
ischemic conditioning (31–33) and for a beta-blocker,
metoprolol (34,35). The differences between pre-
clinical studies conducted by different groups in the
ﬁeld of cardioprotection have recently triggered the
establishment of the National Heart, Lung, and Blood
Institute-sponsored CAESAR consortium (Consortium
for preclinicAl assESsment of cARdioprotective ther-
apies) (36,37).
The question may be “Does reperfusion injury
have an impact on cardiac function that can be
inﬂuenced by speciﬁcally-targeted interventions?”
(38–40). First, considering the overall results of
the latest trials in which highly promising agents/
maneuvers were tested, it appears that reperfusion
either accounts for a much lower fraction of overall
ischemia/reperfusion injury or may be extremely
difﬁcult to effectively target in real-world clinical
practice. Atar et al. (28) reported no LV function
improvement in terms of end-diastolic and end-
systolic volume, evaluated by 2-dimensional echo-
cardiography on days 3 to 5 and 30 days after hospital
admission. These results match the 90-day lack of
LVEF improvement reported in exenatide-treated
PERSPECTIVES
COMPETENCY IN MEDICAL KNOWLEDGE: Intravenous
administration of cyclosporine A immediately before primary
coronary angioplasty within 6 h from the onset of symptoms in
patients with STEMI did not improve markers of myocardial
injury, ventricular remodeling, or clinical outcomes, indicating
that this strategy did not prevent or reduce reperfusion-related
injury.
TRANSLATIONAL OUTLOOK: Additional research is needed
to identify more effective adjunctive strategies to attenuate
ischemia/reperfusion injury in patients with STEMI undergoing
pPCI.
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373patients, although the drug increased myocardial
salvage by 15% (29).
Finally, although of limited clinical relevance,
the safety proﬁle of intravenous CsA in acute MI,
assessed in the CYCLE and CIRCUS trials, can exclude
the risk of allergic reactions (24–26). The nonstatisti-
cally signiﬁcant excess of mortality in CYCLE with CsA
was not conﬁrmed by the larger CIRCUS study (16).
STUDY LIMITATIONS. The main limitation of the
present trial is the use of echocardiography instead of
magnetic resonance, which is the preferred imaging
technique for studies of cardioprotection, given the
possibility of estimating a myocardial salvage index.
However, the limited accessibility of this technique in
the 31 participating Italian Centers of the National
Health Service and its high cost hampered its use in a
multicenter, investigator-driven clinical trial, such as
the CYCLE trial. Therefore, echocardiography with a
stringent protocol, central validation, and quality
control was adopted.
The study was slightly underpowered because the
calculated target of 444 patients was not reached and
410 patients were enrolled. However, it is unlikely
that a positive ﬁnding was missed because of insuf-
ﬁcient power, given the lack of evidence even for only
a positive trend in any of the variables measured. The
potential bias originating from the lack of blinding
was mitigated by use of central randomization and
the PROBE design.
CONCLUSIONS
The consistent results on ST-segment resolution,
cardiac biomarkers, echocardiography, and clinical
events strongly support our observation that CsA
does not reduce ischemia/reperfusion injury when
given intravenously just before pPCI in acute MItreated within 6 h from the onset of symptoms.
Further research is needed to gain additional insight
into the nature of reperfusion injury as a potential
therapeutic target.
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